Results 241 to 250 of about 3,679,356 (272)

Use of hypomethylating agents in myelodysplastic syndromes.

Clinical advances in hematology & oncology : H&O, 2007
Aberrant DNA methylation is one of the molecular hallmarks of cancer and leukemia. By repressing gene expression, it is considered a functional equivalent to the physical inactivation of tumor suppressor genes by deletions or mutations. To clinically exploit this process, compounds with DNA hypomethylating properties have been evaluated both in the ...
Ehab, Atallah, Guillermo, Garcia-Manero
openaire   +1 more source

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.

Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis, 2022
Eleonora De Bellis, S. Imbergamo, A. Candoni, A. Liço, I. Tanasi, E. Mauro, F. Mosna, M. Leoncin, M. Stulle, D. Griguolo, S. Pravato, L. Trentin, D. Lazzarotto, E. di Bona, R. Bassan, E. Lucchini, M. Poiani, C. Palmieri, F. Zaja   +18 more
semanticscholar   +1 more source

Acute Myocarditis Induced by Hypomethylating Agents

Journal of Clinical Oncology, 2011
Jean-Emmanuel, Bibault, Nathalie, Cambier, Jean-Michel, Lemahieu, Bruno, Quesnel, Marine, Auffret, Christian, Rose   +5 more
openaire   +2 more sources

Treatment of Hematologic Malignancies with DNA Hypomethylating Agents

2013
The azanucleosides 5-azacytidine (5-aza, Vidaza) and its deoxyribonucleoside analog 5-aza-2′ deoxycytidine (decitabine), while first synthesized and shown to have/possess [besitzen] antileukemic activity in 1964, have only recently been approved for the treatment of myeloid neoplasias.
Michael Daskalakis, Tina E. Joeckel, Michael Lübbert, A. Kuendgen   +3 more
openaire   +1 more source

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

Leukemia
S. Shimony, J. Bewersdorf, R. Shallis, Yiwen Liu, E. J. Schaefer, A. Zeidan, A. Goldberg, E. Stein, Guido Marcucci, R. C. Lindsley, Evan C Chen, Jorge M. Ramos Perez, A. Stein, D. DeAngelo, D. Neuberg, Richard M. Stone, B. Ball, Maximilian F. Stahl   +17 more
semanticscholar   +1 more source

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents

Nature Medicine, 2020
C. Riether, T. Pabst, S. Höpner, U. Bacher, Magdalena Hinterbrandner, Y. Banz, Rouven Müller, M. Manz, W. Gharib, D. Francisco, R. Bruggmann, L. van Rompaey, M. Moshir, Tim Delahaye, D. Gandini, Ellen Erzeel, A. Hultberg, S. Fung, H. de Haard, N. Leupin, A. Ochsenbein   +20 more
semanticscholar   +1 more source

Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options

Current Hematologic Malignancy Reports, 2021
Daniel R. Richardson, Steven D Green, M. Foster, J. Zeidner   +3 more
semanticscholar   +1 more source

Hypomethylating Agents

2008
openaire   +1 more source

A safe and effective DNA hypomethylating agent

Nature Reviews Drug Discovery, 2021
openaire   +1 more source

Cancer Chemotherapeutic Agents

Ca-A Cancer Journal for Clinicians, 1981
exaly   +2 more sources